Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?

Wojciech Łężak; Łukasz Mokros; Jakub M. Kaźmierski; Dominik Strzelecki; Hanna Jerczyńska; Edward Kowalczyk; Tadeusz Pietras

doi:10.5114/ppn.2020.103632

eISSN: 2720-5371
ISSN: 1230-2813

Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii

Current issue Archive Manuscripts accepted About the journal Scientific board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

Open access

4/2020
vol. 29

Send email

Copy url:

abstract:

Original paper

Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?

Wojciech Łężak

¹

,

Łukasz Mokros

²

,

Jakub M. Kaźmierski

³

,

Dominik Strzelecki

⁴

,

Hanna Jerczyńska

⁵

,

Edward Kowalczyk

¹

,

Tadeusz Pietras

^{2, 6}

Department of Pharmacology and Toxicology, Medical University of Lodz, Poland
Department of Clinical Pharmacology of the 1st Chair of Internal Diseases, Medical University of Lodz, Poland
Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland
Department of Affective and Psychotic Disorders, Medical University of Lodz, Poland
Central Scientific Laboratory (CoreLab), Medical University of Lodz, Poland
Department of Neuroses, Personality Disorders and Eating Disorders, Institute of Psychiatry and Neurology, Warsaw, Poland

Adv Psychiatry Neurol 2020; 29 (4): 205-214

DOI: https://doi.org/10.5114/ppn.2020.103632

Online publish date: 2021/01/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Łężak W, Mokros Ł, Kaźmierski J, et al. Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2020;29(4):205-214. doi:10.5114/ppn.2020.103632.

APA

Łężak, W., Mokros, Ł., Kaźmierski, J., Strzelecki, D., Jerczyńska, H.,  & Kowalczyk, E. et al. (2020). Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 29(4), 205-214. https://doi.org/10.5114/ppn.2020.103632

Chicago

Łężak, Wojciech, Łukasz Mokros, Jakub M. Kaźmierski, Dominik Strzelecki, Hanna Jerczyńska, Edward Kowalczyk,  and Tadeusz Pietras. 2020. "Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?". Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii 29 (4): 205-214. doi:10.5114/ppn.2020.103632.

Harvard

Łężak, W., Mokros, Ł., Kaźmierski, J., Strzelecki, D., Jerczyńska, H., Kowalczyk, E.,  and Pietras, T. (2020). Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 29(4), pp.205-214. https://doi.org/10.5114/ppn.2020.103632

MLA

Łężak, Wojciech et al. "Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?." Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, vol. 29, no. 4, 2020, pp. 205-214. doi:10.5114/ppn.2020.103632.

Vancouver

Łężak W, Mokros Ł, Kaźmierski J, Strzelecki D, Jerczyńska H, Kowalczyk E et al. Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2020;29(4):205-214. doi:10.5114/ppn.2020.103632.

PlumX metrics:

Introduction
Physical activity (PA) is considered to be a major preventive factor in psychopharmacotherapy-induced metabolic adverse effects, such as metabolic syndrome induction. The recent discovery of irisin might bring a potential tool with which to supervise patient compliance or create an additional metabolic risk assessment parameter

Material and methods
The sample consisted of 66 in- and out-patients of a Polish hospital. Irisin serum concentrations were measured using commercially available ELISA kits. Sociodemographic and clinical data were obtained from medical records. PA sufficiency was assessed with the use of the International Physical Activity Questionnaire. t-Student, c2 , Fisher’s exact test, Pearson correlation and ANCOVA were used for statistical analysis. The significance level was set at α = 0.05.

Results
The difference in irisin concentrations between patients with sufficient and insufficient PA was not statistically significant. Patients given second generation antipsychotic drugs exhibited lower PA and irisin concentrations than patients on antidepressant drugs or first-generation antipsychotic drugs. Additionally, irisin concentrations were lower in patients with central obesity compared to patients without it.

Conclusions
Irisin does not appear to be a valid, objective tool for the evaluation of patients. However, significant associations between irisin concentrations, psychopharmacotherapy and metabolic parameters were found.

keywords:

Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?

Wojciech Łężak 1 , Łukasz Mokros 2 , Jakub M. Kaźmierski 3 , Dominik Strzelecki 4 , Hanna Jerczyńska 5 , Edward Kowalczyk 1 , Tadeusz Pietras 2, 6

metabolic syndrome, antipsychotics, antidepressants, psychopharmacotherapy, irisin

Wojciech Łężak

¹

,

Łukasz Mokros

²

,

Jakub M. Kaźmierski

³

,

Dominik Strzelecki

⁴

,

Hanna Jerczyńska

⁵

,

Edward Kowalczyk

¹

,

Tadeusz Pietras

^{2, 6}